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TWICE-DAILY INTRAVENOUS (IV) BUSULFAN (BU) X 4 DAYS IN CHIL-
DREN UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION (ALLOHSCT) IS PHARMACOKINETICALLY SIMILAR TO Q6
HOUR DOSING IN THE PEDIATRIC POPULATION
Waxman, I.1, Milone, M.C.2, Bhatia, M.1, Shaw, L.2, Moore, V.1,
Tallamy, B.1, Militano, O.1, Garvin, J.H.1, George, D.1,
Bradley, M.B.1, Satwani, P.1, Schwartz, J.3, Wolownik, K.1, Foley, S.1,
Hawks, R.1, Baxter-Lowe, L.A.4, van de Ven, C.1, Cairo, M.S.1,3,5 1Co-
lumbia University, New York, NY; 2University of Pennsylvania, Philadel-
phia, PA; 3Columbia University, New York, NY; 4University of
California, San Francisco, CA; 5Columbia University, New York, NY
Busulfan (Bu) is often used as part of the conditioning regimen for
pediatric patients undergoing allogeneic (allo) stem cell transplanta-
tion (SCT). Current pediatric dosing recommendations are based on
age and weight, with children 4 years of age or younger receiving
a higher every 6 hour (q6h) dose (1 mg/kg/dose) than children older
than 4 (0.8 mg/kg/dose) (Wall et al, Blood, 2000a). Twice-daily
(q12h) dosing is an attractive alternative to q6h dosing, requiring
less nursing time and less accessing of the patient’s central venous
catheter. Twice-daily dosing is not currently in wide use, however,
as IV Bu has a narrow therapeutic range and there is no published
data confirming that q12h pharmacokinetics (PK) are comparable
to q6h PK. From April 2003 to November 2007, 42 pediatric pa-
tients (age # 21 yrs) with malignant (n 5 16) and nonmalignant (n
5 26) conditions underwent alloSCT (23 unrelated cord blood, 3 re-
lated cord blood, 8 matched unrelated donor peripheral blood or
marrow, 8 matched family donor peripheral blood or marrow)
with preparative regimens including IV Bu q12h x 8 doses (3.2mg/
kg/day, 4 mg/kg/day if age # 4 yrs) and subsequent IV Bu PK anal-
ysis. Patients received phenytoin/fosphenytoin seizure prophylaxis
and FK506/MMF GVHD prophylaxis. PK samples were obtained
at hr 1, 2, 3, 5, 6, 7 and 8 after start of 1st dose. Bu levels were mea-
sured by a GC-MS method on heparinized plasma. PK results were
compared to PK data from pediatric q6h dosing historical controls
derived from the literature (Booth et al, J Clin Pharmacol, 2007)
and from the database of the Toxicology Laboratory of the Hospital
of the University of Pennsylvania. IV Bu q12h clearance (Cl) and vol-
ume of distribution (Vd) point estimates (n 5 38) were similar to
published PK results for q6h dosing in the pediatric population
(q6 vs. q12h Cl [L/h]: 4.04 vs 4.46, respectively; q6 vs. q12h Vd
[L]: 12.8 vs. 13.3, respectively). There was no statistically significant
difference between the steady-state concentrations (Css) (n 5 35)
achieved with q12h dosing when compared to q6h patients well-
matched for age and weight (n5 90) in the University of Pennsylva-
nia database (7376 239 ng/mL vs. 6736 164 ng/mL, p5 0.25; q6h
vs. q12h, respectively). No patients developed VOD. This data sug-
gests that IV Bu q12h in children has a PK profile similar to q6h dos-
ing and is safe, while providing the benefits of reduced nursing time
and less accessing of the patient’s central venous catheter.201
INTRAVENOUS AND INTRATHECAL ENZYME REPLACEMENT BEFORE
AND AFTER HEMATOPOIETIC CELL TRANSPLANTATION FOR HURLER
SYNDROME
Tolar, J.1, Dickson, P.2, Orchard, P.J.1 1University of Minnesota School of
Medicine, Minneapolis, MN; 2Los Angeles Biomedical Research Institute
at Harbor-UCLA Medical Center, Los Angeles, CA
Hurler syndrome (HS; mucopolysaccharidosis type I) is a lyso-
somal storage disorder caused by a deficiency of iduronidase, with re-
sultant accumulation of glycosaminoglycans in viscera and brain.
Hematopoietic cell transplantation (HCT) has been shown to be
a life-saving measure for children with HS. To decrease the toxicity
of HCT we have offered intravenous iduronidase enzyme replace-
ment therapy (IV ERT) before and after HCT. Twelve children
with HS at a median age of 1.5 years at the time of myeloablativeHCT were eligible. Iduronidase (0.58 mg/kg/dose) was adminis-
tered intravenously in 11–14 weekly doses before HCT and 8 weekly
doses after HCT. The infusions were well tolerated. All patients de-
veloped antibodies to iduronidase, but on day 100 had.90% donor
hematopoiesis, suggesting that ERT prior to HCT is unlikely to al-
ter donor engraftment. All are alive and well, with a median follow-
up of more than 1 year after HCT. Patients with HS, however, also
develop central nervous system (CNS) pathology, and IV-adminis-
tered iduronidase has been shown ineffective in crossing the
blood-brain barrier. Encouraged by the results of intrathecal ERT
(IT ERT) studies in the animal model of HS, we reasoned that clin-
ical investigations incorporating IT ERT, IV ERT, and HCT may
provide increased benefit to HS patients. To date, we have enrolled
3 patients with HS on this IT ERT study. The dose administered is
0.05 mg/kg iduronidase in 3 mL of Elliot’s B solution. Four doses of
drug are administered: the first beginning at the time of IV ERT, the
second just prior to transplantation, the third 100 days post HCT,
and the last 180 days post transplantation. This timing was chosen
to deliver enzyme to the brain until it is anticipated that donor mi-
croglial cells are present in sufficient numbers to deliver enzyme to
the CNS. At present, one patient has received all doses, while the
others continue on study. The 2 patients who were transplanted
are alive and fully engrafted at day 100. Magnetic resonance imaging
and cerebrospinal fluid analysis at the time of IT ERT showed no ev-
idence of brain inflammation. Our data thus demonstrate that mul-
timodal cellular and enzyme therapy in HS is feasible. Importantly,
it affirms the safety of IT ERT, IV ERT, and HCT combination
therapy, and provides a rationale for application of this strategy to
additional HS patients in order to assess fully its impact on long-
term neuropsychological function of HS patients.202
PREENGRAFTMENT C-REACTIVE PROTEIN PREDICTS INFECTION RISK
AND NONRELAPSE MORTALITY IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
McNeer, J.1, Duerst, R.1, Jacobsohn, D.1, Rademaker, A.2, Kletzel, M.1
1Children’s Memorial Hospital, Northwestern University Feinberg School
of Medicine, Chicago, IL; 2Northwestern University Feinberg School of
Medicine, Chicago, IL
Hematopoetic stem cell transplantation (HSCT) is used success-
fully in children to treat a variety of disorders. Despite known clin-
ical risk factors, predicting which patients will develop major
complications remains difficult, and transplant-related mortality
approaches 20%. C-reactive protein (CRP) is an acute phase reac-
tant produced by hepatocytes in response to tissue damage, infec-
tion, and inflammation, and it has been shown to be a reliable
marker of systemic inflammation. Studies in adults have demon-
strated that elevated CRP may predict transplant complications,
specifically the development of acute graft-versus-host disease
(aGVHD) and non-relapse mortality (NRM). If similar findings
can be demonstrated in children, it may be possible to identify at-
risk patients who would benefit from more vigilant observation
during their transplant. We enrolled 70 patients (median age, 10
years; range: 3 months–20 years) undergoing allogeneic HSCT at
our institution, drew CRP levels at days 0 and 7, and analyzed
data based on the higher of these values for each patient. We
collected the following demographic information: age, gender,
disease, conditioning regimen and stem cell source. The develop-
ment of complications within 100 days, including severe infection
(defined as gram-negative bacteremia, fungal infections, or other
infections associated with hypotension/sepsis), aGVHD, hepatic
veno-occlusive disease, engraftment failure, relapse and NRM,
was recorded for each patient. Using the Wilcoxon rank sum test,
elevated CRP values were significantly associated with myeloabla-
tive versus reduced-intensity conditioning regimen (p 5 0.003),
malignant versus non-malignant disease (p 5 0.03), subsequent
significant infections (p 5 0.0005), and non-relapse mortality
(p 5 0.02). Conditioning regimen, infection, and non-relapse
mortality remained significant after multivariate analysis (p 5
0.002, p 5 0.0005, and p 5 0.03, respectively). On ROC analysis,
a CRP value .4.35 was 70% sensitive and 72% specific for
development of severe infection, and a CRP value of .7.05 was
72% sensitive and 78% specific for NRM. We did not find a
Poster Session-I 75statistically significant association between elevated CRP and
grades 0/1 versus grades 2–4 aGVHD (p5 0.1) or grades 0–2 versus
grades 3–4 aGVHD (p 5 0.21). Our data suggest that following
CRP values for the first seven days in patients undergoing HSCT




Variable Status N (Min/Max) p-value p-valueDiagnosis Malignant 50 4.37 (0.1/27.7) 0.03 0.16
Non-malignant 20 1.29 (0.31/24)Conditioning
RegimenMyeloablative 37 6.45 (0.39/24.6) 0.003 0.002Reduced Intensity 33 1.3 (0.1/27.7)
Donor Matched Sibling 32 3.8 (0.1/24.6) 0.26 –Alternative Donor 38 2 (0.21/27.7)
aGVHD Grades 0/I 52 2.75 (0.1/27.7) 0.1 –Grades II-IV 18 6.67 (0.32/24.6)
aGVHD Grades 0-II 60 3.15 (0.1/27.7) 0.21 –Grades III-IV 10 11.45 (0.32/23.2)
Severe
Infection
Yes 27 8.03 (0.1/27.7) 0.0005 0.0005No 43 1.64 (0.21/24.6)
Non-Relapse
Mortality
Yes 9 12.6 (0.77/27.7) 0.02 0.03No 61 2.44 (0.1/24.6)203
SINGLE INSTITUTION VALIDATION OF RISK ADJUSTED OUTCOMES FOR 1
YEAR MORTALITY IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLAN-
TATION (HSCT)
Duerst, R.E.1, Halverson, T.L.1, Reynolds, N.1, Jacobsohn, D.1,
Rademaker, A.2, Kletzel, M.1 1Children’s Memorial Hospital, Northwest-
ern University, Feinberg School of Medicine, Chicago, IL; 2Northwestern
University, Feinberg School of Medicine, Chicago, IL
To effectively compare center’s outcomes, patients (pts) need to be
risk-adjusted. Risk adjustment factors in pediatric and adult HSCT
are likely to be different. A risk score predictive of 1-year treat-
ment-related mortality (TRM) for pediatric pts undergoing alloge-
neic HSCT has been published (Matthes-Martin, BBMT, 2008
(14) p 335) using data from German and Austrian centers. In this ret-
rospective analysis three factors were significant to predict the risk
for 1-year TRM: age . 10, alternative donor and advanced disease.
We evaluated several factors that could potentially affect the out-
come of allogeneic HSCT for pediatric pts. All pts undergoing allo-
geneic HSCT at Children’s Memorial Hospital from 2005–2007 (n
5 111) were evaluated. We retrospectively analyzed the following
variables: age, presence of malignancy, status of disease and high-
risk disease features such as cytogenetic or molecular markers, type
of conditioning (myeloablative vs. reduced intensity), use of TBI,
prior transplant, existence of co-morbidities, cell source , Matthes-
Martin score, and degree of HLA match between donor and recipi-
ent with respect to 100-day and 1-year survival using Fisher’s exact
test (see Table). In our cohort of patients, degree of match (8 of 8
vs.#7 of 8) was significantly related to 100 day (p 5 0.001) and 1
year (p 5 0.004) mortality. All other factors analyzed were not pre-
dictive of mortality. The Matthes-Martin score of $2 (n 5 26) ap-
proached significance with respect to 100 day mortality (p 5 0.06)
but was not predictive for 1-year mortality (p5 0.36). Potential dif-
ferences in our pts from the Matthes-Martin pts include: younger
median age (6.5 vs 8.7yrs), fewer malignancy pts (61 vs 72%), fewer
marrow HSC (12 vs 50%) and more PBSC (67 vs 49%) in our cohort.
In conclusion, because of the diversity of patients in both cohorts we
could not validate the Matthes-Martin score for risk adjusted mortal-
ity in our center. Further analyses of larger cohorts of patients are re-
quired to evaluate this method. These characteristics in turn, need to
be validated at individual centers and over time as supportive care
evolves.Potential Risk Factors for Pediatric HSCT
1-year
Patient Characteristic N 100-day Mortality P value* mortality P value*All patients 111 15 (14%) 24 (22)
Malignancy 68 8 (12%) 15 (22%)
Non-malignancy 43 7 (16%) n.s. 9 (21%) n.s.
Myeloablative 49 6 (12%) 12 (24%)
Reduced Intensity 62 9 (15%) n.s. 12 (19%) n.s.
HSC Source: umbilical
cord blood
24 4 (17%) 6 (25%)HSC source: bone
marrow13 2 (15%) n.s. 4 (31%) n.s.HSC source: peripheral
blood stem cells74 9 (12%) n.s. 14 (19%) n.s.Maathes-Martin
score 0-185 8 (9%) 16 (19%)Maathes-Martin
score $226 7 (27%) p 5 0.06 8 (31%) p 5 0.36HLA* matched (8 of 8) 67 3 (4%) 8 (12%)
HLA* match #7 of 8 44 12 (27%) p 5 0.00116 (36%) p 5 0.004*P value calculated using Fisher Exact Test; HLA match at A, B, C and
DRb1 loci204
REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT) IN CHILDREN AND ADOLESCENT RECIP-
IENTS IS ASSOCIATED WITH VERY LOW REGIMEN RELATED AND NON-
RELAPSE MORTALITY (NRM): HOWEVER, CHEMONAIVE PATIENTS
FOLLOWING UMBILICAL CORD BLOOD TRANSPLANT (UCBT) HAVE A
HIGHER INCIDENCE OF PRIMARY GRAFT FAILURE (PGF)
Satwani, P.1, Tallamy, B.1, Jin, Z.4, Kohl, V.1, Garvin, J.1, Bhatia, M.1,
George, D.1, Bradley, B.1, van de Ven, C.1, Reichman, L.1, Morris, E.1,
Fearon, N.1, Harrison, L.1, Shonfeld, T.1, Baxter-Lowe, L.A.2,
Schwartz, J.3, Hawks, R.1, Foley, S.1, Cairo, M.S.1,3,5 1Columbia Uni-
versity, New York, NY; 2University of California, San Franisco, CA; 3Co-
lumbia University, New York, NY; 4Columbia University, New York,
NY; 5Columbia University, New York, NY
Myeloablative-AlloSCT is associated with a 20–40% NRM in the
first 100 days post AlloSCT. RIC may decrease this high mortality
but data in pediatric recipients is limited (Satwani/Cairo et al,
BBMT 2005; PBC 2007). We evaluated the feasibility and toxicity
of RI-AlloSCT in 83 children and adolescents with malignant (n 5
47) and non-malignant (n 5 36) disease: Median age 10 6 6.7yrs,
UCB (n5 42), matched family donor (MFD) (n5 32), matched un-
related donor (MUD) (n 5 9); average risk (n 5 72), poor risk (n 5
11). Busulfan (6.4–8mg/kg)1fludarabine (150–180mg/m2)6ATG
(8mg/m2) (n 5 45); cyclophospamide (60mg/kg)1fludarabine
(150mg/m2)6ATG (8mg/m2) (n 5 18); and busulfan (12.8–16mg/
kg)1fludarabine (150mg/m2)1alemtuzumab (54mg/ m2) (n 5 20).
Median follow-up is 951 6 776d. Median time to neutrophil and
plt recovery was 16 (CI95; 15,18) and 33 (CI95;30,48) days, respec-
tively. The probability of neutrophil and plt recovery was 96.1 6
2.2% and 83 6 4.3%, respectively. Median chimerism on day 30,
60, 100 and 365 was 95% vs 97% vs 98% and 99%, respectively.
The probability of aGVHD (Gr I-IV) was 30 6 5% in all pts and
15.4 6 5.7% in pts with UCB and 41.2%68.79% in MFD (p 5
.015). The probability of cGVHD was 20 6 5.3% in all pts and 10
6 5.7% in pts with UCB and 38.5%69.68% in MFD (p 5 .006).
The incidence of PGF was 13.8 6 3.86%. The incidence of PGF
in UCBT was 28.2 6 7.2% vs 0% in MFD or MUD (p 5 0.0014).
The incidence of PGF in UCBT chemo-naı¨ve pts was 50 6 11%
vs non-chemo naı¨ve was 5.3 6 5% (p 5 0.002). On univariate anal-
ysis for PGF, gender, regimen, disease risk status, CMV status, UCB
cell dose and HLA match did not reach statistical significance; age
(p5 0.19), non-malignant disease (p5 0.05) and chemo-naı¨ve status
(p5 0.03) reached statistical significance. However, in a multivariate
analysis age (p 5 0.2), non-malignant disease (p 5 0.8) and chemo-
naı¨ve status (p 5 0.06) did not achieve statistical significance. The
day 100 NRM was 3 6 2% and overall NRM was 14.7 6 4.5%.
The incidence of serious adverse events (gr III-IV) was 12.5%.
The 1 and 5yr OS for pts with malignant diseases was 71.1 6 6.7
